Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMA

ImageneBio Inc

Healthcare · Biotechnology

$4.10

Up+$0.05 (+1.23%)

Updated Nov 1, 2026, 8:53 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
72.57M
P/E ratio
-10.19
Dividend yield
0.00%
52-week range
$3.88 – $6.64
Volume
5.67K
Avg. volume
69.97K

Price performance · IMA

IMA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

IMA closed at $4.10 after 20 trading sessions, down 12.77% for the selected period.

Last close
$4.10
Period change
-12.77%
Period low
$4.00
Period high
$4.70
Daily close
View OHLC price history
IMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$4.05$4.21$4.05$4.105.67K
Oct 29, 2026$4.15$4.15$4.04$4.054.65K
Oct 28, 2026$4.02$4.4499$4.02$4.2024.39K
Oct 27, 2026$4.0799$4.11$4.02$4.024.14K
Oct 26, 2026$4.15$4.42$3.88$4.0532.9K
Oct 23, 2026$3.98$4.30$3.98$4.227.87K
Oct 22, 2026$4.08$4.115$4.045$4.0456.19K
Oct 21, 2026$4.14$4.18$4.07$4.0857.09K
Oct 20, 2026$4.00$4.29$3.98$4.1322K
Oct 19, 2026$4.00$4.13$3.99$4.006.06K
Oct 16, 2026$4.15$4.15$4.00$4.049.86K
Oct 15, 2026$4.26$4.26$3.982$4.0321.57K
Oct 14, 2026$4.20$4.20$4.14$4.150520.75K
Oct 13, 2026$4.16$4.25$4.0549$4.2410.12K
Oct 12, 2026$4.29$4.29$4.00$4.2528.05K
Oct 9, 2026$4.17$4.31$3.90$4.248.12K
Oct 8, 2026$4.48$4.48$4.00$4.2630.08K
Oct 7, 2026$4.60$4.61$4.60$4.612.24K
Oct 6, 2026$4.70$4.72$4.60$4.6013.74K
Oct 5, 2026$4.6016$4.73$4.6016$4.708.53K

Latest IMA news

The latest Smart Investors Daily articles mentioning IMA.

Stock researchCompany · Overview

IMA research

Overview

Company profile and research snapshot.

Company profile

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.33
Implied upside
—
Analysts
—
IMA recent ratings
DateFirmRatingTarget
Aug 21, 2026HC Wainwright & Co.Buy—
May 11, 2026WedbushUnderperform—
Oct 24, 2025Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements material to the new empl

Yahoo · Sep 8, 2026

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and management will participate in one-on-one meetings. H.C. Wainwright 28th Annual Global Investment Conference in New YorkFireside Chat: Monday, Sept. 14, 2026, 3:30pm ETWebcast linked here and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By